Commercialization challenges associated with induced pluripotent stem cell-based products.
Induced pluripotent stem (iPS) cells have generated excitement in the regenerative medicine industry. Products derived from iPS cells could be used in a range of drug discovery and development processes. These nontherapeutic products will continue to be launched over the next 5 years, and provide income and knowledge to drive the therapeutic use of iPS cells forward. While the commercial opportunity for iPS cell-based therapies is potentially large, the looming technical and scientific hurdles must be overcome and, thus, the launch of a therapy based on iPS cells is unlikely to occur until the 2020s. While the launch of a therapeutic is many years away, the business models for commercialization should be well understood and proven based on experience with other non-iPS cell-based therapies (both autologous and allogeneic) that will already be on the market.
Smith
Devyn
D
Strategic Management Group, Pfizer Global R&D, 50 Pequot Avenue, MS6025-C4171, New London, CT 06320, USA. devyn.m.smith@pfizer.com
D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000637:transplantation*; D008389:Marketing of Health Services / Q000191:economics* / Q000331:legislation & jurisprudence* / Q000639:trends; D044968:Regenerative Medicine